{
    "nctId": "NCT00426751",
    "title": "Eptifibatide Versus Abciximab in Primary PCI for Acute ST Elevation Myocardial Infarction",
    "symPyJSON": {
        "type": "and",
        "operands": [
            {
                "type": "and",
                "operands": [
                    {
                        "type": "variable",
                        "value": "Women must be postmenopausal (i.e.12 months without menstrual period), or surgically sterile"
                    },
                    {
                        "type": "variable",
                        "value": "must have minimum age of 18 Years"
                    },
                    {
                        "type": "or",
                        "operands": [
                            {
                                "type": "variable",
                                "value": "Angina or equivalent symptoms > 20 min"
                            },
                            {
                                "type": "variable",
                                "value": "ST elevation in 2 contiguous ECG leads (>= 2 mm precordial lead, >= 1 mm limb lead)"
                            }
                        ]
                    },
                    {
                        "type": "variable",
                        "value": "Planned primary percutaneous coronary intervention"
                    },
                    {
                        "type": "variable",
                        "value": "The subject has given written informed, dated consent to participate in the study"
                    }
                ]
            },
            {
                "type": "not",
                "operands": [
                    {
                        "type": "or",
                        "operands": [
                            {
                                "type": "variable",
                                "value": "Subjects not able to give informed consent"
                            },
                            {
                                "type": "variable",
                                "value": "Left Bundle Branch Block"
                            },
                            {
                                "type": "variable",
                                "value": "Thrombolytic therapy within 24 hours before randomization"
                            },
                            {
                                "type": "variable",
                                "value": "Oral anticoagulation with International Normalized Ratio (INR) > 2"
                            },
                            {
                                "type": "variable",
                                "value": "Known platelets < 100.000/\u00b5l or known hemorrhagic diathesis"
                            },
                            {
                                "type": "variable",
                                "value": "Stroke or Transient Ischemic Attack (TIA) within the past 6 months or any permanent residual neurological defect"
                            },
                            {
                                "type": "variable",
                                "value": "Evidence of an active gastrointestinal or urogenital bleeding"
                            },
                            {
                                "type": "variable",
                                "value": "Major surgery within 6 weeks"
                            },
                            {
                                "type": "variable",
                                "value": "History of allergic reaction to abciximab or eptifibatide or any component used in the study (including contrast media)"
                            },
                            {
                                "type": "variable",
                                "value": "Known severe renal (creatinine clearance <30ml/min) or hepatic insufficiency as well as Alanine transaminase (ALT)/aspartate transaminase (AST) elevations >= 3xUpper limit normal (ULN)"
                            },
                            {
                                "type": "variable",
                                "value": "Severe concomitant disease with life expectation < 1 year"
                            },
                            {
                                "type": "variable",
                                "value": "Subject has participated in any study using an investigational drug or device within 30 days or within 5 half-lives of the investigational drug (whichever is longer) of entry into this study."
                            },
                            {
                                "type": "variable",
                                "value": "Subjects who will be inaccessible due to geographic or social factors during treatment or follow-up"
                            },
                            {
                                "type": "variable",
                                "value": "In France, a subject is neither affiliated with nor a beneficiary of a social security category."
                            }
                        ]
                    }
                ]
            }
        ]
    },
    "symPyExpression": "And(Symbol('Planned primary percutaneous coronary intervention'), Symbol('The subject has given written informed, dated consent to participate in the study'), Symbol('Women must be postmenopausal (i.e.12 months without menstrual period), or surgically sterile'), Symbol('must have minimum age of 18 Years'), Or(Symbol('Angina or equivalent symptoms > 20 min'), Symbol('ST elevation in 2 contiguous ECG leads (>= 2 mm precordial lead, >= 1 mm limb lead)')), Not(Or(Symbol('Evidence of an active gastrointestinal or urogenital bleeding'), Symbol('History of allergic reaction to abciximab or eptifibatide or any component used in the study (including contrast media)'), Symbol('In France, a subject is neither affiliated with nor a beneficiary of a social security category.'), Symbol('Known platelets < 100.000/\u00b5l or known hemorrhagic diathesis'), Symbol('Known severe renal (creatinine clearance <30ml/min) or hepatic insufficiency as well as Alanine transaminase (ALT)/aspartate transaminase (AST) elevations >= 3xUpper limit normal (ULN)'), Symbol('Left Bundle Branch Block'), Symbol('Major surgery within 6 weeks'), Symbol('Oral anticoagulation with International Normalized Ratio (INR) > 2'), Symbol('Severe concomitant disease with life expectation < 1 year'), Symbol('Stroke or Transient Ischemic Attack (TIA) within the past 6 months or any permanent residual neurological defect'), Symbol('Subject has participated in any study using an investigational drug or device within 30 days or within 5 half-lives of the investigational drug (whichever is longer) of entry into this study.'), Symbol('Subjects not able to give informed consent'), Symbol('Subjects who will be inaccessible due to geographic or social factors during treatment or follow-up'), Symbol('Thrombolytic therapy within 24 hours before randomization'))))"
}